Allon Therapeutics Inc. (TSX:NPC) announced today that a Phase 1 clinical trial of its lead neuroprotective drug, davunetide , which began patient enrolment January 28, 2010, has been completed. The results demonstrated that the intranasal dose range can be broadened and provided additional information on the pharmacokinetic profile of davunetide...